现货型内分支技术治疗真腔狭窄的慢性夹层后胸腹主动脉瘤:欧洲多中心研究结果
该欧洲多中心注册研究评估了现货型预置导管内分支支架(E-nside)治疗主动脉夹层的早期与中期结局。2020年1月至2024年5月共纳入14家高容量欧洲中心的34例患者,技术成功率97%,30天死亡率为6%,平均随访15.1个月无主动脉相关死亡,结论认为该技术可行且短期与中期结局可接受,但需长期随访。
要点
- 34例主动脉夹层患者使用E-nside现货型内分支支架,技术成功率为97%。
- 30天死亡率为6%(n=2),30天再干预率为9%(n=3)。
- 平均随访15.1个月无主动脉相关死亡,随访期间靶血管不稳定发生率为13%(4/32)。
核心结论
- 使用现货型内分支支架血管内治疗主动脉夹层可行,短期和中期结局可接受,技术植入安全性和有效性良好。
- 需要长期随访结果以更好地确定这种新型内支架的临床作用。
研究设计与样本
- 国际多中心注册研究,分析2020年1月至2024年5月期间在14家高容量欧洲机构接受E-nside内支架治疗的主动脉夹层患者数据。
- 共纳入34例患者,平均年龄66±9.8岁,男性30例(88%)。
- 主要终点为技术成功,次要终点包括30天及随访期间的全因死亡、主动脉相关死亡、主动脉相关再干预率、内漏率和靶血管不稳定(TVI)。
主要发现
- 内脏段主动脉真腔平均直径为24.5±7.7 mm,手术时间中位数为300分钟(四分位距215,373)。
- 技术成功率为97%,1例因腹腔干覆膜支架置入肠系膜上动脉分支、反之亦然而未达技术成功。
- 30天死亡率为6%(n=2),30天再干预率为9%(n=3)。
- 平均随访15.1±7.5个月,无主动脉相关死亡,12个月免于主动脉相关死亡率为97%,免于全因死亡率为94%。
- 随访期间TVI发生率为13%(4/32),总再干预率为16%(5/32)。
局限性
- 需要长期随访结果以更好地确定这种新型内支架的临床作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the early and midterm outcomes of endovascular repair of aortic dissection (AD) using a new pre-cannulated, inner branch based, off the shelf stent graft (E-nside; JOTEC, CryoLife, Inc.). METHODS: Data from an international multicentre registry on patients treated with the E-nside endograft for AD were analysed. Pre-operative clinical and anatomical characteristics, procedural data, and early and follow up outcomes were recorded in a dedicated electronic data capture system. The primary endpoint was technical success. Secondary endpoints were overall death, aortic related death, aortic related re-intervention rate, endoleak rate, and target vessel instability (TVI) at 30 days and during follow up. RESULTS: Thirty four patients treated in 14 high volume European institutions between January 2020 and May 2024 were included. The mean patient age ± standard deviation was 66 ± 9.8 years, and 30 (88%) were male. The mean true lumen aortic diameter at the visceral aorta was 24.5 ± 7.7 mm. The median procedure time was 300 minutes (interquartile range 215, 373). The technical success rate was 97%, due to one case of placement of the coeliac trunk covered stent into the branch of the superior mesenteric artery and vice versa. The 30 day mortality and re-intervention rates were 6% (n = 2) and 9% (n = 3), respectively. At a mean follow up of 15.1 ± 7.5 months, there were no aortic related deaths. Freedom from aortic related death and all cause death at 12 months was 97% and 94%, respectively. The TVI rate during the follow up was 13% (four of 32). The total re-intervention rate was 16% (five of 32). CONCLUSION: Endovascular treatment of AD with an off the shelf, inner branched endograft is feasible, with acceptable short and midterm outcomes. The results showed good technical implantation safety and efficacy. Long term follow up results are needed to better define the clinical role of this novel endograft.
引用
- Tinelli G, Lescan M, Sica S, et al. Inner Branch Off the Shelf Technology for Chronic Post-dissection Thoraco-Abdominal Aneurysm with Narrow True Lumen: Results of a European Multicentre Study. Eur J Vasc Endovasc Surg. 2025. PMID: 40288567. doi:10.1016/j.ejvs.2025.04.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。